Skip to main content
AAN.com
Articles
May 7, 2007

Focality of upper and lower motor neuron degeneration at the clinical onset of ALS

May 8, 2007 issue
68 (19) 1571-1575

Abstract

Objective: To localize and analyze the anatomic distribution of upper motor neuron (UMN) and lower motor neuron (LMN) loss in patients with ALS early in their disease when motor manifestations were still relatively focal using clinical examination signs.
Methods: We reviewed records of 100 patients with ALS who were evaluated when the diagnosis was first established or suspected. From the patient history, we ascertained the body region of first symptoms and the time course. From the physical examination, we separately graded severity of UMN and LMN signs in each body region, indexed these to the body region of first symptoms, and sorted and analyzed the data.
Results: Motor manifestations began in one body region in 98% of patients. UMN and LMN signs were both maximal in these same body regions, but they were independent of each other in severity and their outward distribution, which conformed to neuronal anatomy. The outward distribution of both UMN and LMN signs seemed more directed to caudal body regions than to rostral ones.
Conclusions: Motor neuron degeneration in ALS is a focal process at both upper and lower motor neuron levels of the motor system. At each level, it begins corresponding to the same peripheral body region and then advances contiguously and separately to summate over time.

Get full access to this article

View all available purchase options and get full access to this article.

Supplementary Material

File (e1.pdf)
File (e2.pdf)
File (e3.pdf)
File (e4.pdf)
File (e5.pdf)
File (e6.pdf)
File (e7.pdf)

REFERENCES

1.
Gowers WR. Manual of diseases of the nervous system. London: Churchill, 1886–1888 (reprinted special edition, Birmingham, AL: Classics of Medicine Library, 1981).
2.
Jokelainen M. Amyotrophic lateral sclerosis in Finland II: clinical characteristics. Acta Neurol Scandinav 1977;56:194–204.
3.
Mulder DW. Clinical limits of amyotrophic lateral sclerosis. In: Rowland LP, ed. Human motor diseases. New York: Raven Press, 1982, pp 15–22.
4.
Gubbay SS, Kahana E, Zilber N, et al. Amyotrophic lateral sclerosis: a study of its presentation and prognosis. J Neurol 1985;232:295–300.
5.
Caroscio JT, Mulvihill MN, Sterling R, et al. Amyotrophic lateral sclerosis: its natural history. Neurol Clin 1987;5:1–8.
6.
Brooks BR. The role of axonal transport in neurodegenerative disease spread: a meta-analysis of experimental and clinical poliomyelitis compares with amyotrophic lateral sclerosis. Can J Neurol Sci 1991;18:435–438.
7.
DeJong RN. The neurologic examination. incorporating the fundamentals of neuroanatomy and neurophysiology. 4th ed. Hagerstown: Harper & Row, 1979.
8.
Cwik VA. ALS clinical motor signs and symptoms, Chapter 5. In: Mitsumoto H, Przedborski S, Gordon PH, eds. Amyotrophic lateral sclerosis. New York: Taylor & Francis, 2006:99–115.
9.
Tourtellotte WW, Syndulko K. Quantifying the neurologic examination: principles, constraints, and opportunities, Chapter 2. In: Munsat TL, ed. Quantification of neurologic deficit. Boston: Butterworths, 1989:7–16.
10.
Brooks BR, Miller RG, Swash M, et al. El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2000;1:293–299.
11.
DeJong RN. The stretch reflexes, Chapter 33. In: The neurologic examination: Incorporating the fundamentals of neuroanatomy and neurophysiology. 4th ed. Hagerstown: Harper & Row, 1979:431–445.
12.
LaRocca NG. Statistical and methodologic considerations in scale construction, Chapter 5. In: Munsat TL, ed. Quantification of neurologic deficit. Boston: Butterworths, 1989:49–68.
13.
The ALS CNTF Treatment Study (ACTS) Phase I-II Study Group: The Amyotrophic Lateral Sclerosis Functional Rating Scale: assessment of activities of daily living in patients with amyotrophic lateral sclerosis. Arch Neurol 1996;53:141–147.
14.
Brooks BR, DePaul R, Tan YD, et al. Motor neuron disease, Chapter 18. In: Schoenberg BS, Porter R, eds. Controlled clinical trials in neurology. Norwood: Marcel Dekker, 1990:249–281.
15.
Ono M, Kubik S, Abernathey C. Atlas of the cerebral sulci. Stuttgart: Verlag, 1990:151–161.
16.
Ravits J, Fan Y, Laurie P, Cheteni F. Personal observations.
17.
Swash M. Vulnerability of lower brachial myotomes in motor neurone disease: a clinical and single fibre EMG study. J Neurol Sci 1980;47:59–68.
18.
Swash M, Leader M, Brown A, Swettenham KW. Focal loss of anterior horn cells in the cervical cord in motor neuron disease. Brain 1986;109 (pt 5):939–952.
19.
Charcot J-M. Des amyotrophies chroniques—atrophie musculaire progressive spinale prototypique. In: Oeuvres Complètes. Vol 2. Paris: Bureaux du Progrès Mèdical, 1874:221–233. (In English: Chronic spinal amyotrophies: protopathic spinal progressive muscular atrophy. In: Sigerson G, translator. Lectures on diseases of the nervous system. London: New Sydenham Society, 1881:233–248.)
20.
Charcot J-M. Sclérose latérale amyotrophique. In: Oeuvres Complètes. Vol 2. Paris: Bureaux du Progrès Mèdical, 1897:249–266. (In English: Amyotrophic lateral sclerosis: symptomatology. In: Sigerson G, translator. Lectures on diseases of the nervous system. London: New Sydenham Society, 1881:192–204.)
21.
Kiernan JA, Hudson AJ. Changes in sizes of cortical and lower motor neurons in amyotrophic lateral sclerosis. Brain 1991;114:843–853.
22.
Nihei K, McKee AC, Kowall NW. Patterns of neuronal degeneration in the motor cortex of amyotrophic lateral sclerosis. Acta Neuropathol 1993;86:55–64.
23.
Pamphlett R, Kril J, Hng TM. Motor neuron disease: a primary disorder of corticomotor neurons? Muscle Nerve 1995;18:314–318.
24.
Mochizuki Y, Mizutani T, Takasu T. Amyotrophic lateral sclerosis with marked neurological asymmetry: clinicopathological study. Acta Neuropathol 1995;90:44–50.
25.
Sharrard WJW. The distribution of permanent paralysis in the lower limbs in poliomyelitis. J Bone Joint Surg 1955;37B:540–558.
26.
Wohlfart G. Collateral regeneration in partially denervated muscles. Neurol 1958;8:175–180.
27.
Hansen S, Ballantyne JP. A quantitative electrophysiological study of motor neurone disease. J Neurol Neurosurg Psychiatry 1978;41:773–783.
28.
Swash M, Ingram D. Preclinical and subclinical events in motor neuron disease. J Neurol Neurosurg Psychiatry 1988;51:165–168.
29.
de Carvalho M, Swash M. The onset of amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2006;77:388–389.
30.
Porter R, Lemon R. Corticospinal function and voluntary movement. Oxford, UK: Clarendon Press, 1993:421.
31.
Abmayr S, Weydt P. Skeletal muscle in amyotrophic lateral sclerosis: emerging concepts and therapeutic implications. Phys Med Rehabil Clin N Am 2005;16:1091–1097.
32.
Eisen A, Kim S, Pant B. Amyotrophic lateral sclerosis (ALS): a phylogenetic disease of the corticomotorneuron? Muscle Nerve 1992;15:219–228.
33.
Eisen A, Weber M. The motor cortex and amyotrophic lateral sclerosis. Muscle Nerve 2001;24:564–573.
34.
Chou SM, Norris FH. Amyotrophic lateral sclerosis: lower motor neuron disease spreading to upper motor neurons. Muscle Nerve 1993;9:864–869.

Information & Authors

Information

Published In

Neurology®
Volume 68Number 19May 8, 2007
Pages: 1571-1575
PubMed: 17485643

Publication History

Published online: May 7, 2007
Published in print: May 8, 2007

Permissions

Request permissions for this article.

Authors

Affiliations & Disclosures

John Ravits, MD, FAAN
From the Sections of Neurology (J.R., P.P.), Neuro-Rehabilitation (C.J.), and the ALS Clinic at Virginia Mason (J.R., P.P., C.J.), Virginia Mason Medical Center, Seattle; and Neurogenomics Laboratory (J.R.), Benaroya Research Institute at Virginia Mason, Seattle, WA.
Piper Paul, RN
From the Sections of Neurology (J.R., P.P.), Neuro-Rehabilitation (C.J.), and the ALS Clinic at Virginia Mason (J.R., P.P., C.J.), Virginia Mason Medical Center, Seattle; and Neurogenomics Laboratory (J.R.), Benaroya Research Institute at Virginia Mason, Seattle, WA.
Cathy Jorg, BA
From the Sections of Neurology (J.R., P.P.), Neuro-Rehabilitation (C.J.), and the ALS Clinic at Virginia Mason (J.R., P.P., C.J.), Virginia Mason Medical Center, Seattle; and Neurogenomics Laboratory (J.R.), Benaroya Research Institute at Virginia Mason, Seattle, WA.

Notes

Address correspondence and reprint requests to Dr. John Ravits, Neurogenomics Laboratory, Benaroya Research Institute at Virginia Mason, 1201 Ninth Avenue, Seattle, WA 98101 [email protected]

Metrics & Citations

Metrics

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

Cited By
  1. The burden of upper motor neuron involvement is correlated with the bilateral limb involvement interval in patients with amyotrophic lateral sclerosis: a retrospective observational study, Neural Regeneration Research, 20, 5, (1505-1512), (2024).https://doi.org/10.4103/NRR.NRR-D-23-01359
    Crossref
  2. Physiological Biomarkers of Upper Motor Neuron Dysfunction in ALS, Brain Sciences, 14, 8, (760), (2024).https://doi.org/10.3390/brainsci14080760
    Crossref
  3. Automatic detection of ALS from single-trial MEG signals during speech tasks: a pilot study, Frontiers in Psychology, 15, (2024).https://doi.org/10.3389/fpsyg.2024.1114811
    Crossref
  4. Potential contribution of spinal interneurons to the etiopathogenesis of amyotrophic lateral sclerosis, Frontiers in Neuroscience, 18, (2024).https://doi.org/10.3389/fnins.2024.1434404
    Crossref
  5. Association Between Hypothalamic Volume and Metabolism, Cognition, and Behavior in Patients With Amyotrophic Lateral Sclerosis, Neurology, 103, 2, (2024)./doi/10.1212/WNL.0000000000209603
    Abstract
  6. The Lateral Corticospinal Tract Sign: An MRI Marker for Amyotrophic Lateral Sclerosis, Radiology, 312, 3, (2024).https://doi.org/10.1148/radiol.231630
    Crossref
  7. Spinal inhibitory neurons degenerate before motor neurons and excitatory neurons in a mouse model of ALS, Science Advances, 10, 22, (2024).https://doi.org/10.1126/sciadv.adk3229
    Crossref
  8. A comparison between bioelectrical impedance analysis and air-displacement plethysmography in assessing fat-free mass in patients with motor neurone diseases: a cross-sectional study, Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 25, 3-4, (326-335), (2024).https://doi.org/10.1080/21678421.2023.2300963
    Crossref
  9. Decoding mitochondrial quality control mechanisms: Identifying treatment targets for enhanced cellular health, Mitochondrion, 78, (101926), (2024).https://doi.org/10.1016/j.mito.2024.101926
    Crossref
  10. Novel approaches to assessing upper motor neuron dysfunction in motor neuron disease/amyotrophic lateral sclerosis: IFCN handbook chapter, Clinical Neurophysiology, 163, (68-89), (2024).https://doi.org/10.1016/j.clinph.2024.04.010
    Crossref
  11. See more
Loading...

View Options

Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Purchase Options

The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.

If you need immediate support or to place an order, please call or email customer service:

  • 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
  • 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
  • [email protected]

We appreciate your patience during this time and apologize for any inconvenience.

View options

PDF and All Supplements

Download PDF and Supplementary Material

Full Text

View Full Text

Full Text HTML

View Full Text HTML

Media

Figures

Other

Tables

Share

Share

Share article link

Share